Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY
Price: $4.11 Analyst target: $7.00 Upside: 70.32%
Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for the administration of polypeptides. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.